news
Advances in Influenza Vaccine Production
Influenza viruses require an acidic endosomal environment to uncoat and replicate efficiently. Standard Vero cells struggle with sufficient acidification, creating a yield bottleneck in cell-culture-based vaccine manufacturing. In a new publication in Vaccine, our collaborators at Capricorn Technologies, alongside Evercyte, LT Biotech, and the Slovak Medical University, present AEX-1: a novel Vero cell variant engineered to overcome this exact bottleneck. 💡 Key Findings: [...]
Our microRNA toolbox has a new look
Anyone working with microRNAs knows the problem: there are a lot of databases and analysis tools, and it isn’t always obvious which one fits your research question. Plus, every year new tools are released that facilitate the functional analysis of microRNAs. That’s why we reworked our overview of web-based microRNA tools. It is now live with a new design. The biggest change is [...]
What does a positive test result really mean? Try our Predictive Value Explorer
A test with 90% sensitivity and 90% specificity sounds reliable. But use it for screening, where 1 in 100 people has the disease, and fewer than 1 in 10 positive results will be true positives. Our new Predictive Value Explorer shows why. Sensitivity and specificity describe how well a test detects disease in samples with a known diagnosis. Patients and doctors ask a [...]
New evidence on variability of plasma miR-122 published with contribution of TAmiRNANew evidence on variability of plasma miR-122 published with contribution of TAmiRNA
biomarker, circulating miRNAs, DILI, drug-induced liver injury, microRNA services, miND, miND spike ins, RNA, small RNA-sequencing, smallRNA, TransBioLine
New evidence on variability of plasma miR-122 published with contribution of TAmiRNA
A short communication published in the British Journal of Clinical Pharmacology re-evaluates the inter- and intra-individual variability of circulating miR-122 in healthy volunteers, using small RNA sequencing generated on TAmiRNA's miND workflow (Javid et al., 2026, doi:10.1002/bcp.70836). Background MicroRNA-122 (miR-122) is a liver-enriched circulating microRNA and one of the most extensively studied candidate biomarkers for drug-induced liver injury (DILI). A 2019 evaluation by [...]
TAmiRNA Joins Six European RNA Specialists to Launch the European RNA AllianceTAmiRNA Joins Six European RNA Specialists to Launch the European RNA Alliance
biomarker, circulating miRNAs, ERA, European RNA Alliance, EV characterization, exosomes, extracellular vesicle, microRNA services, miND, miND spike ins, RNA, small RNA-sequencing, smallRNA
TAmiRNA Joins Six European RNA Specialists to Launch the European RNA Alliance
As a founding member of ERA, TAmiRNA positions itself as the innovative driving force behind RNA biomarker development in Europe — combining novel biomarker products with premier research services in cell-free RNA and EV/exosome analysis. Vienna, Austria — September 8, 2026 TAmiRNA is proud to announce that it has joined six other independent European RNA companies — Anemocyte, Genevia Technologies, Immagina Biotechnology, Lexogen, [...]
TAmiRNA is a Silver Sponsor at the D-A-CH EV Meeting 2026 in ErlangenTAmiRNA is a Silver Sponsor at the D-A-CH EV Meeting 2026 in Erlangen
biomarker, circulating miRNAs, Conference, EV characterization, exosomes, extracellular vesicle, microRNA services, miND, miND spike ins, RNA, small RNA-sequencing, smallRNA
TAmiRNA is a Silver Sponsor at the D-A-CH EV Meeting 2026 in Erlangen
From September 28–30, 2026, the D-A-CH EV Meeting 2026 will take place at the Hörsaalzentrum of the Medical Faculty, University Hospital Erlangen — the first joint annual meeting of the German, Austrian and Swiss societies for extracellular vesicles (GSEV, ASEV and SwissEV). Under the motto "Extracellular Vesicles: Communication Across Barriers," around 300 to 350 international scientists from the EV field will gather in [...]
TAmiRNA at the 5th MC/WG Meeting of COST Action AtheroNET in Prague
From September 2–4, 2026, the COST Action AtheroNET (CA21153) network will gather for its 5th Management Committee and Working Group meeting at the University of Chemical Technology in Prague. AtheroNET is supported by COST (European Cooperation in Science and Technology) and connects European research groups working on new approaches to understanding and diagnosing atherosclerosis. The three-day programme promises intensive scientific exchange: from a [...]
TAmiRNA CEO Dr. Matthias Hackl to Lecture on microRNA Biomarker Development at Jyväskylä Summer School 2026TAmiRNA CEO Dr. Matthias Hackl to Lecture on microRNA Biomarker Development at Jyväskylä Summer School 2026
biomarker, circulating miRNAs, Conference, microRNA, microRNA services, miND, miND spike ins, miND spike-in, NGS, RNA, small RNA-sequencing, smallRNA
TAmiRNA CEO Dr. Matthias Hackl to Lecture on microRNA Biomarker Development at Jyväskylä Summer School 2026
Our CEO Dr. Matthias Hackl, a leading expert in microRNA biomarker discovery, small RNA sequencing, and IVD development, has been invited as a lecturer at this year's Jyväskylä Summer School at the University of Jyväskylä, Finland. As part of the course BIO1: MicroRNA Biology and Function (4–6 August 2026), he will join an international team of experts from Helsinki, Kuopio, and Jyväskylä to [...]
Circulating microRNAs Reveal Molecular Effect of Zoledronic Acid on Tendon-to-Bone Healing
New publication in the American Journal of Sports Medicine, co-authored by TAmiRNA Retears remain a common complication after arthroscopic rotator cuff repair. A recent study by researchers from the AUVA Trauma Center Vienna-Meidling, the Ludwig Boltzmann Institute for Traumatology, the Austrian Cluster for Tissue Regeneration, and TAmiRNA now sheds light on the molecular mechanism behind a promising augmentation strategy: a single intraoperative dose [...]
Why Spike-ins Are the Key to Reproducible Small RNA-seq Data
Reproducibility is one of the biggest challenges in small RNA sequencing – and at the same time one of the most critical requirements for valid biomarker studies. Whether you are comparing data across batches, running multi-laboratory studies, or working with disease cohorts that show shifts in global RNA content: without an external reference, there is no reliable anchor to make your data truly [...]
